This is a working overview of Peptide bond, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-08-27. Anything still debated is marked as such rather than presented as settled.
Whey protein hydrolysate is a dairy ingredient made by treating whey protein with proteases that cleave peptide bonds. The starting material is typically whey protein concentrate or isolate, which contains beta-lactoglobulin, alpha-lactalbumin, and smaller amounts of bovine serum albumin and immunoglobulins. Hydrolysis shortens protein chains into peptides and free amino acids, changing solubility, viscosity, and flavor compared with intact whey protein. The extent of cleavage is commonly described by degree of hydrolysis, a percentage of broken peptide bonds relative to total bonds.
Enzyme choice influences the peptide size distribution and the resulting functional properties. Some proteases cut at specific amino acid residues, while others act more broadly, so two hydrolysates with the same degree of hydrolysis can differ in peptide sequences. Short peptides are generally more water-soluble and less likely to form gels under heat, although bitterness can increase when hydrophobic residues become exposed. The relationship between peptide length, taste, and bioactivity is an active area of study, and not all proposed effects are established in human trials.
Whey protein hydrolysate is a dairy ingredient made by breaking peptide bonds in whey proteins. Enzymes such as proteases, or in some processes acid or heat, cleave the protein chains into shorter peptides and free amino acids. The starting material may be sweet whey, acid whey, whey protein concentrate, or whey protein isolate. Because raw materials and reaction conditions differ, the final mixture is not a single uniform substance. Its peptide profile, mineral content, and residual lactose depend on the source and the processing steps used.
Production typically begins with pasteurization and concentration of whey. A protease is added under controlled temperature and pH, and the reaction is stopped by heat or pH change when the target extent of cleavage is reached. Ultrafiltration or diafiltration may remove enzymes, salts, and small molecules. The liquid is then spray dried into a powder. Process parameters shape bitterness, solubility, and peptide size. Established control points include enzyme type, reaction time, and inactivation conditions. How these variables interact across large-scale batches remains an area of active process development.
| Property | Value | Notes |
|---|---|---|
| Appearance | Off-white to pale yellow powder | Color varies with hydrolysis and drying |
| Solubility class | Highly soluble in water | Short peptides often dissolve more readily than intact protein |
| Typical protein content | 70-90% dry basis | Depends on starting material and purification |
| Degree of hydrolysis | 2-30% commonly reported | Method and calculation vary |
| Common synonyms | Hydrolyzed whey protein; whey protein hydrolysate | Labels may use either order |
Whey protein hydrolysate is made by cleaving peptide bonds in whey proteins. The starting material is usually whey protein concentrate or isolate obtained during cheese or casein production. Proteolytic enzymes, acid, or heat can drive hydrolysis, although commercial processes favor controlled enzymatic treatment. The degree of hydrolysis describes the proportion of peptide bonds broken and separates partial from extensive hydrolysates. The resulting powder contains short peptides, free amino acids, residual intact protein, minerals, lactose, and fat in proportions that depend on the starting whey and downstream filtration.
Molecular weight distribution is a central compositional feature, and hydrolysis shifts the population toward lower-mass peptides, often below ten kilodaltons in extensively treated products. Enzyme choice, reaction time, temperature, pH, and enzyme-to-substrate ratio influence the peptide profile. Ultrafiltration or diafiltration may remove enzymes, salts, and smaller molecules. Because peptide size affects solubility, taste, foaming, and digestibility, manufacturers specify molecular weight ranges. However, two hydrolysates with similar average molecular weight can differ in peptide sequence and functional behavior.
Enzymatic hydrolysis usually uses proteases from microbial, plant, or animal sources. The enzyme choice, pH, temperature, and reaction time determine which peptide bonds are cleaved and the final peptide profile. After hydrolysis, the enzyme is inactivated by heat, and the mixture is clarified, filtered, concentrated, and spray-dried. Manufacturers may use ultrafiltration to remove larger peptides or minerals. The degree of hydrolysis, often reported as a percentage, describes the proportion of peptide bonds broken. A higher degree generally means shorter peptides, but it does not by itself define taste, allergenicity, or biological activity.
Whey protein hydrolysate appears in foods, infant formula, sports nutrition, and specialized clinical nutrition. Its production can reduce viscosity and improve heat stability compared with intact whey protein. Bitterness is common because short hydrophobic peptides can activate bitter taste receptors. The ingredient is not the same as free amino acids; it remains a mixture of peptides of different lengths. Composition varies by supplier, enzyme, and process, so two hydrolysates with the same protein content may behave differently in a formulation.
φ29’s DNA packaging system, using pRNA, incorporates a motor for the delivery of therapeutic molecules like ribozymes and aptamers. The small size of pRNA-derived nanoparticles also helps to deliver drugs in tight spaces like blood vessels. The main difficulty in using aptamer-based drug delivery is sourcing unique aptamers and other multimers for specific treatments for diseases that potentially degrade therapeutic multimers and nanoparticles in vivo. Nanoparticles need to be stabilized as delivery mechanisms in order to adapt to microenvironments that may result in loss of therapeutic cargo.
The centrifugal partition chromatograph instrument is constituted with a unique rotor which contains the column. This rotor rotates on its central axis (while HSCCC column rotates on its planetary axis and simultaneously rotates eccentrically about another solar axis). With less vibrations and noise, the CPC offers a typical rotation speed range from 500 to 2000 rpm. Contrary to hydrodynamic CCC, the rotation speed is not directly proportional to the retention volume ratio of the stationary phase. Like DCCC, CPC can be operated in either descending or ascending mode, where the direction is relative to the force generated by the rotor rather than gravity. A redesigned CPC column with larger chambers and channels has been named centrifugal partition extraction (CPE). In the CPE design, faster flow rates and increased column loading can be achieved.
Affinity chromatography can be used in a number of applications, including nucleic acid purification, protein purification from cell free extracts, and purification from blood. By using affinity chromatography, one can separate proteins that bind to a certain fragment from proteins that do not bind that specific fragment. Because this technique of purification relies on the biological properties of the protein needed, it is a useful technique and proteins can be purified many folds in one step.
Sources: en.wikipedia.org
Chromosome 11 open reading frame 91, or C11orf91 is a protein which in humans is encoded by the C11orf91 gene. The C11orf91 gene consists of 5159 nucleotides with an mRNA of approximately 836 base pairs. There is one exon found in the C11orf91 gene. The cytogenetic band location of C11orf91 is 11p13 and is located on the minus strand of the DNA . Annotated depiction of the C11orf91 mRNA and amino acid protein sequences. The C11orf91 gene encodes a protein that is 193 amino acids in length. The C11orf91 protein contains a domain of unknown function, DUF5529, that spans nearly the entire protein. RBMX protein binding sites were found to be highly conserved in several structures of human C11orf91 3'UTR and 5' UTR. C11orf91 is rich in serine and proline and poor in valine and asparagine. There is a proline rich region found in the middle of the C11orf91. The human C11orf91 protein is approximately 20 kDal and has an isoelectric point around 9. Human C11orf91 protein is predicted to be localized in vesicles. C11orf91 has two helices located near the C-terminus and no beta sheets.
Anaerobic sulfide oxidation is performed by both phototrophs and chemotrophs. Green sulfur bacteria (GSB) and purple sulfur bacteria (PSB) perform anoxygenic photosynthesis fueled by sulfide oxidation. Some PSB can also perform aerobic sulfide oxidation in the presence of oxygen and can even grow chemoautotrophically under low light conditions. GSB lack this metabolic potential and have compensated by developing efficient light harvesting systems. PSB can be found in various environments ranging from hot sulfur springs and alkaline lakes to wastewater treatment plants. GSB populate stratified lakes with high reduced sulfur concentrations and can even grow in hydrothermal vents by using infra-red light to perform photosynthesis. Hydrothermal vents emit hydrogen sulfide that support the carbon fixation of chemolithotrophic bacteria that oxidize hydrogen sulfide with oxygen to produce elemental sulfur or sulfate. The chemical reactions are as follows:
Class I ARE elements, like the c-fos gene, have dispersed AUUUA motifs within or near U-rich regions. Class II elements, like the GM-CSF gene, have overlapping AUUUA motifs within or near U-rich regions. Class III elements, like the c-jun gene, are a much less well-defined class—they have a U-rich region but no AUUUA repeats. No real ARE consensus sequence has been determined yet, and these categories are based neither on the same biological functions, nor on the homologous proteins.
Sources: en.wikipedia.org
AS9000 (1997) Aerospace Basic Quality System Standard As aerospace suppliers soon found that ISO 9001 (1994) did not address the specific requirements of their customers, including the DoD, NASA, FAA, and commercial aerospace companies including Boeing, Lockheed Martin, Northrop Grumman, GE Aircraft Engines and Pratt & Whitney, they developed AS9000, based on ISO 9001, to provide a specific quality management standard for the aerospace industry. Prior to the adoption of an aerospace specific quality standard, various corporations typically used ISO 9001 and their own complementary quality documentation/requirements, such as Boeing's D1-9000 or the automotive Q standard. This created a patchwork of competing requirements that were difficult to enforce and/or comply with. The major American aerospace manufacturers collaborated to develop a unified quality standard based on ISO 9001:1994, which led to the creation of AS9000. Following its release, companies like Boeing discontinued their previous quality supplements in favor of complying with AS9000.
Life expectancy of people with acromegaly is dependent on how early the disease is detected. Life expectancy after the successful treatment of early disease is equal to that of the general population. Acromegaly can often go on for years before diagnosis, resulting in poorer outcome, and it is suggested that the better the growth hormone is controlled, the better the outcome. Upon successful surgical treatment, headaches and visual symptoms tend to resolve. One exception is sleep apnea, which is present in around 70% of cases but does not tend to resolve with successful treatment of growth hormone level. While hypertension is a complication of 40% of cases, it typically responds well to regular regimens of blood pressure medication. Diabetes that occurs with acromegaly is treated with the typical medications, but successful lowering of growth hormone levels often alleviates symptoms of diabetes. Hypogonadism without gonad destruction is reversible with treatment. Acromegaly is associated with a slightly elevated risk of cancer.
Recycling chromatography is mode practiced in both HPLC and CCC. In recycling chromatography, the target compounds are reintroduced into the column after they elute. Each pass through the column increases the number of theoretical plates the compounds experience and enhances chromatographic resolution. Direct recycling must be done with an isocratic solvent system. With this mode, the eluant can be selectively re-chromatographed on the same or a different column in order to facilitate the separation. This process of selective recycling has been termed a "heart-cut" and is especially effective in purifying selected target compounds with some sacrificial loss of recovery. The process of re-separating selected fractions from one chromatography experiment with another chromatographic method has long been practiced by scientists. Recycling and sequential chromatography is a streamlined version of this process. In CCC, the separation characteristics of the column may be modified simply by changing the composition of the biphasic solvent system.
The Swiss company GlycArt Biotechnology developed a system using CHO cells, where the cells were engineered to overexpress an enzyme called GnTIII. The effect of this overexpression is to block the formation of fucosylated oligosaccharides on the expressed antibodies. This technology was first reported in 1999 and was the basis of GlycArt Biotechnology. Roche acquired GlycArt in 2005 in order to acquire technology to afucosylate antibodies. GlycArt Biotechnology had been founded in 2000 as a spin-out company of the Swiss Federal Institute of Technology in Zurich. The first commercial product from the GlycArt acquisition was obinutuzumab, which as Gazyva gained FDA approval in November 2013 for the treatment of chronic lymphocytic leukemia. Kyowa Hakko Kirin's "Potelligent" platform uses a CHO cell line in which FUT8 has been knocked out, and which produces antibodies with little to no fucose in the Fc region. The company gained marketing approval in Japan in April 2012 for a monoclonal antibody drug called mogamulizumab which was developed using the platform. The Company's technology was first reported in 2004.
Sources: en.wikipedia.org
Hydrolysate has undergone enzymatic cleavage of peptide bonds, while isolate is largely intact protein. Both can originate from the same whey stream, but hydrolysis changes peptide size, solubility, taste, and allergenicity testing outcomes. The two ingredients are not interchangeable in every formulation.
No. A higher degree of hydrolysis means more peptide bonds have been broken, which can increase solubility and reduce viscosity but also raise bitterness and processing cost. The best degree depends on the intended use, such as a beverage, bar, or culture medium.
No. They differ by starting whey material, enzyme type, hydrolysis conditions, and downstream purification. These variables produce different peptide profiles, mineral contents, and functional properties. Two products with the same label category may therefore behave differently.
Hydrolysis extent indicates the share of peptide bonds that have been cleaved. It is often estimated from free amino groups and is reported as a percentage. A higher value means smaller peptides and more free amino acids, but it does not by itself define product quality.